Home Newsletters Intestinal Cell News Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase IIA Trial...

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase IIA Trial for the Treatment of Gastroparesis

By
Justin.choi
-
0
Processa Pharmaceuticals, Inc., announced that it has enrolled its first patient in the Phase IIA clinical trial of PCS12852 in patients with moderate to severe gastroparesis.
[Processa Pharmaceuticals, Inc.]
6445212 AAAAAAAA items 1 apa 0 default asc 1 173808 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
Press Release

RELATED ARTICLES

Exit mobile version